CTX611 (SRSD107) — Clinical data readout
H2 2026
The Company expects to provide an update in the second half of 2026.Source filing
CRSP biotech catalysts & pipeline
CRISPR THERAPEUTICS AG · Data as of 2026-10-25
Upcoming catalysts
zugocabtagene geleucel (zugo-cel; formerly CTX112™) — Clinical data readout
H2 2026
In immuno-oncology, the Phase 1/2 clinical trial of zugo-cel in B-cell malignancies is ongoing, with updates anticipated in the second half of 2026.Source filing
CTX321™ — Conference presentation
2026
CTX321 is currently in IND/CTA-enabling studies, with an Lp(a) program update expected in 2026.Source filing
CTX310® — Conference presentation
Nov 9
CRISPR Therapeutics AG ZUG, Switzerland and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310®, its investigational CRISPR/Cas9 in vivo gene editing therapy targeting angiopoietin-related protein 3 (ANGPTL3), in patients with severe hypertriglyceridemia will be presented in a late-breaking oral presentation at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6 – 9, 2026.Source filing